Evidence map›Paper›PMID 30090420›Full record

ArticleToxicology research2016

MicroRNA-21 activation of Akt

Xiaolin Lu, Yang Liu, Fei Luo, Aihua Zhang, Xinlu Liu, Lu Lu, Le Shi, Jun Li, Junchao Xue, Hui Xu and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Toxicology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Xiaolin LuInstitute of Toxicology , School of Public Health , Nanjing Medical University , Nanjing 211166 , Jiangsu , People's Republic of China . Email: drqzliu@hotmail.com ; ; Tel: +86-25-8686-8424.
Yang LiuDepartment of Orthopedics , The First Affiliated Hospital , Nanjing Medical University , Nanjing 210029 , Jiangsu , People's Republic of China.
Fei LuoInstitute of Toxicology , School of Public Health , Nanjing Medical University , Nanjing 211166 , Jiangsu , People's Republic of China . Email: drqzliu@hotmail.com ; ; Tel: +86-25-8686-8424.
Aihua ZhangThe Key Laboratory of Environmental Pollution Monitoring and Disease Control , Ministry of Education , School of Public Health , Guiyang Medical University , Guiyang 550025 , Guizhou , People's Republic of China.
Xinlu LiuInstitute of Toxicology , School of Public Health , Nanjing Medical University , Nanjing 211166 , Jiangsu , People's Republic of China . Email: drqzliu@hotmail.com ; ; Tel: +86-25-8686-8424.
Lu LuInstitute of Toxicology , School of Public Health , Nanjing Medical University , Nanjing 211166 , Jiangsu , People's Republic of China . Email: drqzliu@hotmail.com ; ; Tel: +86-25-8686-8424.
Le ShiInstitute of Toxicology , School of Public Health , Nanjing Medical University , Nanjing 211166 , Jiangsu , People's Republic of China . Email: drqzliu@hotmail.com ; ; Tel: +86-25-8686-8424.
Jun LiThe Key Laboratory of Environmental Pollution Monitoring and Disease Control , Ministry of Education , School of Public Health , Guiyang Medical University , Guiyang 550025 , Guizhou , People's Republic of China.
Junchao XueInstitute of Toxicology , School of Public Health , Nanjing Medical University , Nanjing 211166 , Jiangsu , People's Republic of China . Email: drqzliu@hotmail.com ; ; Tel: +86-25-8686-8424.
Hui XuInstitute of Toxicology , School of Public Health , Nanjing Medical University , Nanjing 211166 , Jiangsu , People's Republic of China . Email: drqzliu@hotmail.com ; ; Tel: +86-25-8686-8424.
Weimin FanDepartment of Orthopedics , The First Affiliated Hospital , Nanjing Medical University , Nanjing 210029 , Jiangsu , People's Republic of China.
Qizhan LiuInstitute of Toxicology , School of Public Health , Nanjing Medical University , Nanjing 211166 , Jiangsu , People's Republic of China . Email: drqzliu@hotmail.com ; ; Tel: +86-25-8686-8424.
Nanjing Medical University · CNState Council of the People's Republic of China · CNGuiyang Medical University · CNIn-Q-Tel · USNanjing Library · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs are involved in the epithelial-mesenchymal transition (EMT) and malignant transformation of cells. However, the molecular mechanisms remain unclear. In seeking new biomarkers of chemical exposure in the risk assessment of arsenite-induced skin cancer, the function of microRNA-21 (miR-21) in the regulation of serine/threonine kinase (Akt) activation was investigated. Akt suppresses phosphatase and tensin homolog (PTEN) and is involved in neoplastic and metastatic properties of arsenite-transformed human keratinocyte (T-HaCaT) cells. In HaCaT cells, arsenite caused an increase of miR-21 levels and a decrease of PTEN, which activated Akt signaling and induced the EMT. On inhibiting miR-21, the levels of PTEN were increased, and activation of Akt was blocked. Knock-down of PTEN by siRNA enhanced the activation of Akt. The effects of an miR-21 inhibitor on Akt activation were antagonized by PTEN siRNA. In T-HaCaT cells, blocking the activation of Akt by LY294002 inhibited the EMT. Moreover, the effects of an miR-21 mimic on the EMT and the neoplastic capacity, invasion, and metastasis of T-HaCaT cells were antagonized by LY294002. T-HaCaT transfected with PTEN plasmids showed decreased Akt activation and E-cadherin expression and increased vimentin levels. Thus, activation of Akt, controlled by miR-21/PTEN, is involved in the EMT, and thereby affects the neoplastic, invasion, and migratory capacities of T-HaCaT cells. The results point to the potential use of miR-21 as a biomarker for skin cancer and as a target for cancer prevention and treatment.

Identifiers

PMID30090420
PMCPMC6062343
OpenAlexW2345522086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.